Literature DB >> 16430679

Exercise performance in hypoxia after novel erythropoiesis stimulating protein treatment.

C Lundby1, R Damsgaard.   

Abstract

Maximal aerobic power at high altitude (<4000 m) does not increase with altitude acclimatization. In order to investigate the isolated effects of increased arterial oxygen content (CaO2) on maximal oxygen uptake (VO2max) in hypoxia, we studied 10 subjects during exercise in acute exposure to 12.6% O2 before and after novel erythropoiesis stimulating protein (NESP) induced increases in CaO2. Over a period of 1 month, weekly NESP treatment increased resting hemoglobin (Hb) from 13.8+/-0.9 to 16.2+/-0.5 g/dL, hematocrit from 42.1+/-0.6% to 49.0+/-1.5%, and CaO2 from 189.7+/-3.0 to 218.6+/-5.7 mL/L. At maximal exercise CaO2 was increased from 172.3+/-3.7 to 191.5+/-3.8 mL/L with NESP treatment, and although maximal heart rate was similar in both conditions (178.4+/-2.6 and 180.9+/-2.5 b.p.m.) VO2max remained unaltered, the values being 3.12+/-2.0 and 3.12+/-2.0, before and after NESP treatment, respectively. NESP-injections in human subjects causes Hb and accordingly CaO2 to increase both in normoxia and hypoxia. Despite increases in CaO2 at maximal exercise in hypoxia VO2max is not increased.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430679     DOI: 10.1111/j.1600-0838.2004.00434.x

Source DB:  PubMed          Journal:  Scand J Med Sci Sports        ISSN: 0905-7188            Impact factor:   4.221


  11 in total

Review 1.  .VO2max: what do we know, and what do we still need to know?

Authors:  Benjamin D Levine
Journal:  J Physiol       Date:  2007-11-15       Impact factor: 5.182

Review 2.  Red blood cell volume and the capacity for exercise at moderate to high altitude.

Authors:  Robert A Jacobs; Carsten Lundby; Paul Robach; Max Gassmann
Journal:  Sports Med       Date:  2012-08-01       Impact factor: 11.136

Review 3.  Effects of recombinant human erythropoietin in normal humans.

Authors:  Carsten Lundby; Niels Vidiendal Olsen
Journal:  J Physiol       Date:  2010-08-31       Impact factor: 5.182

4.  Severity of arterial hypoxaemia affects the relative contributions of peripheral muscle fatigue to exercise performance in healthy humans.

Authors:  Markus Amann; Lee M Romer; Andrew W Subudhi; David F Pegelow; Jerome A Dempsey
Journal:  J Physiol       Date:  2007-02-22       Impact factor: 5.182

5.  Maximal exercise and muscle oxygen extraction in acclimatizing lowlanders and high altitude natives.

Authors:  Carsten Lundby; Mikael Sander; Gerrit van Hall; Bengt Saltin; José A L Calbet
Journal:  J Physiol       Date:  2006-03-31       Impact factor: 5.182

Review 6.  Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit.

Authors:  Jules A A C Heuberger; Joost M Cohen Tervaert; Femke M L Schepers; Adriaan D B Vliegenthart; Joris I Rotmans; Johannes M A Daniels; Jacobus Burggraaf; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

7.  During hypoxic exercise some vasoconstriction is needed to match O2 delivery with O2 demand at the microcirculatory level.

Authors:  Carsten Lundby; Robert Boushel; Paul Robach; Kirsten Møller; Bengt Saltin; José A L Calbet
Journal:  J Physiol       Date:  2007-10-11       Impact factor: 5.182

8.  Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.

Authors:  Kyoung Heo; Joong Koo Kang; Chang Min Choi; Moo Song Lee; Kyoung Woo Noh; Soon Bae Kim
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

9.  The ergogenic effect of recombinant human erythropoietin on VO2max depends on the severity of arterial hypoxemia.

Authors:  Paul Robach; Jose A L Calbet; Jonas J Thomsen; Robert Boushel; Pascal Mollard; Peter Rasmussen; Carsten Lundby
Journal:  PLoS One       Date:  2008-08-20       Impact factor: 3.240

10.  AltitudeOmics: the integrative physiology of human acclimatization to hypobaric hypoxia and its retention upon reascent.

Authors:  Andrew W Subudhi; Nicolas Bourdillon; Jenna Bucher; Christopher Davis; Jonathan E Elliott; Morgan Eutermoster; Oghenero Evero; Jui-Lin Fan; Sonja Jameson-Van Houten; Colleen G Julian; Jonathan Kark; Sherri Kark; Bengt Kayser; Julia P Kern; See Eun Kim; Corinna Lathan; Steven S Laurie; Andrew T Lovering; Ryan Paterson; David M Polaner; Benjamin J Ryan; James L Spira; Jack W Tsao; Nadine B Wachsmuth; Robert C Roach
Journal:  PLoS One       Date:  2014-03-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.